Qianhai Health Holdings Limited Overview
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Employees (year-end, headcount) | — | 16 | 19 |
Qianhai Health Holdings is, despite its name, today essentially a Hong Kong-based independent trader of memory semiconductors — predominantly NAND flash wafers, embedded multi-chip package (eMCP) memory and general electronic components — that sources from upstream distributors and resells to a highly concentrated group of trade customers, with a small, recently revived sideline in ginseng wine, skin-care and health products. Originally the Hang Fat American-ginseng wholesaler, the group pivoted into electronic components in July 2019 under its current controlling shareholder, Mr. Huang Zhiqun, a veteran electronic-components distributor. The business is thin-margin (gross margin 3.5% in FY2025), asset-light (19 staff, one office and warehouse), debt-free, and highly exposed to memory price cycles, as demonstrated by a HK$233.7 M loss in FY2022 on inventory and onerous-contract write-downs. Its equity value is roughly a quarter of book, reflecting cyclicality, customer concentration (top customer 69% of FY2025 sales) and an unresolved receivership over the controlling 52.67% stake.
The company's own description (paraphrased from AR2025)
In AR2025 the board describes the group as principally engaged in the sale of electronic component products (the "Electronic Component Business") and health-care products and food (the "Health-Care Business"). The electronic components operation is characterised as a seller of semiconductors and other electronic components specialising in digital storage products such as NAND flash wafers and general electronic components, with a business model built on identifying, sourcing and distributing products from reputable upstream manufacturers. The company says it benefits from a broad, established customer and supplier base, many with long-standing relationships with the directors, and that its suppliers are mainly component distributors and electronics/IT corporations. For the health-care business, the company says it re-entered the health products sector during 2025 with a refined offering of ginseng wine (positioned as a premium dietary supplement), skin-care and body-care products, and is still building supplier networks, customer relationships and market presence.
Independent characterisation
Stripped of the label, Qianhai Health is a principal-basis memory-chip trading house operating in the Hong Kong spot and contract market for NAND flash. Several features define it:
-
No manufacturing, no design, no proprietary IP. The group adds value through procurement access, working capital, warehousing/quality control and the directors' relationships. The 2022 interim report mentioned value-added services such as warehousing and quality control for customers.
-
Principal risk-taking on inventory. The group alternates between (i) back-to-back procurement matched to confirmed customer orders and (ii) "strategic bulk procurement" based on management's price view. In FY2025 it explicitly shifted toward bulk buying to capture rising NAND prices (AR2025). This is effectively a directional position on memory prices; it generated a HK$230.0 M inventory provision and HK$93.2 M onerous-contract provision in FY2022 when the cycle turned (FY2023 inside-information announcement, 8 Feb 2024).
-
Prepayment-heavy working capital. Suppliers require deposits of 15–20% (FY2025; 15–30% in FY2024) within three business days of an order, with the balance paid before delivery (AR2025). Customers receive 30–180 days' credit. The company therefore finances the cycle on both sides out of equity.
-
Extreme concentration. In FY2025 the largest customer accounted for ~69% and the top five ~92% of sales; the largest supplier ~26% and top five ~90% of purchases (AR2025). None are related parties according to the directors.
-
Single-geography revenue recognition. All revenue is recognised in Hong Kong based on the location of delivery (FY2024 RA note 3), though end-demand is driven by PRC and Asian electronics manufacturers.
-
Health-care segment is residual. It contributed ~10% of FY2025 revenue (AR2025) but only HK$2.25 M (≈2%) in 1H2026 (1H2026 IR).
Revenue model mix
| Revenue type | Share of FY2025 revenue | Comment |
|---|---|---|
| Product sales — electronic components (principal basis, point-in-time recognition) | >90% | NAND flash wafers, eMCP memory, other components (AR2025; FY2024 RA note 3) |
| Product sales — health-care products and food | ~10% | Ginseng wine, skin-care, body-care, Chinese herbal products (AR2025) |
| Services | 0% | No separately reported service revenue |
| Subscription / licensing | 0% | — |
| Interest income (other income, not revenue) | De minimis | HK$0.22 M interest on short-term third-party loans in FY2024 (FY2024 RA note 4) |
Value-chain position
Upstream memory manufacturers (Samsung, SK hynix, Kioxia/Western Digital (now Sandisk), Micron, YMTC — not named by the company) → franchised/authorised distributors and large PRC trading companies (the group's suppliers) → Qianhai Health (independent trader/broker, Hong Kong) → module makers, SSD/eMMC/USB assemblers, OEM/ODM manufacturers and other traders (the group's customers, mostly PRC/Asia, delivered in Hong Kong) → consumer electronics, data-centre SSD, mobile, automotive end-markets.
In 2022 the group signed a master sale and purchase agreement with what it described as one of the largest trading companies in the PRC as a supplier, securing a steady source of components (Interim Report 2022). Management's stated aspiration (AR2025) is to move up the chain into manufacturing facilities in the PRC and elsewhere offering customisation, assembly, packaging and testing.
Customer types and end-markets
| Customer type | End-markets served | Evidence |
|---|---|---|
| Electronics manufacturers, module houses and traders (Hong Kong delivery) | Storage (SSD, eMMC/UFS, USB), mobile devices, consumer electronics, data-centre infrastructure, automotive electronics | AR2025 MD&A cites AI, 5G, data centres and automotive as demand drivers |
| Health-product wholesalers and retailers in Hong Kong | Traditional Chinese health tonics, dietary supplements, skin/body care | AR2025 ESG report (sales to wholesalers and retailers in Hong Kong) |
Strategy
Stated strategic themes (paraphrased from AR2025 Prospects and FY2024 RA Future Prospects)
-
Ride structural semiconductor growth — third-generation semiconductors, 5G, AI and automotive electronics are framed as long-term growth drivers; management expects the NAND wafer shortage to persist in the near term and intends to use supplier relationships to secure inventory where possible.
-
Move into value-added manufacturing — plan to invest in new manufacturing facilities in the PRC and elsewhere, enabling technical support, product customisation, assembly, packaging and testing.
-
R&D partnerships and own products — collaboration with technology companies and research institutions; FY2024 RA also referred to sourcing R&D investments to create its own products and build brand influence.
-
Rebuild the health-care segment — talks with potential partners in skincare and healthcare supplements; sourcing body-care products; pursuit of authorised-distributor relationships with manufacturers.
-
Supply-chain resilience — reduce exposure to geopolitical issues and material shortages.
-
Inorganic growth — pursue investments and acquisitions of promising projects for medium- to long-term returns.
-
Product-agency optimisation (FY2024 RA) — optimise product agency layout, expand the product matrix and strengthen supply-chain cooperation.
Initiatives announced or executed in the last 24 months
| Initiative | Date | Status / evidence | Targets |
|---|---|---|---|
| Shift from back-to-back to strategic bulk procurement | FY2025 | Executed; inventory rebuilt to HK$231 M by Jun 2026 | None disclosed |
| Ginseng wine, skin-care launch (health-care re-entry) | FY2025 | ~10% of FY2025 revenue; HK$2.25 M in 1H2026 | None disclosed |
| Share consolidation (10:1) | 20 May 2024 | Completed | — |
| New share option scheme | 27 Jun 2024 | Adopted; no grants | Mandate 16.94 M shares |
| Disposal of Huge Hope Group | 28 Nov 2024 | Completed; HK$51.9 M gain | — |
| Board reconstitution (two new EDs, new audit chair) | Aug–Nov 2024 | Completed | — |
| Cost control | 1H2026 | Admin expenses −27.9% to HK$6.8 M | None disclosed |
| PRC manufacturing facilities | Announced in AR2025 (Apr 2026) | No capex committed; AR2025 states no specific plans for material investments or capital assets | None disclosed |
| ESG — carbon/energy | FY2025 | Target to keep emissions and energy "at a similar low level" | Qualitative only |
Medium-term financial targets / guidance
The company provides no quantitative medium-term targets or guidance. Its only forward-looking quantitative disclosures are statutory profit alerts (e.g., 13 Feb 2026 positive profit alert for FY2025; 24 Jul 2026 profit warning guiding a 35–45% decline in 1H2026 profit — actual decline 36.7%).
Products & Services
The company does not publish a product catalogue, price list or brand architecture. The following is the complete set of product lines disclosed in filings since 2016.
Electronic component products segment
| Product line | Description & capabilities | Target customer | First disclosed / latest | Pricing model | Flagship / named offerings |
|---|---|---|---|---|---|
| NAND flash wafers | Thin silicon wafers carrying NAND flash dies, the core input for flash ICs (SSD, eMMC/UFS, USB, cards). AR2025 notes TLC wafers saw the sharpest shortages in 2025 | Module makers, SSD/eMMC assemblers, packaging houses, traders | Disclosed from FY2023–FY2024; core line in FY2025–1H2026 | Spot/contract market pricing; principal margins of ~3–7% | Upstream brands not disclosed |
| eMCP memory (embedded multi-chip package) | Single package combining NAND (eMMC) and mobile DRAM; used in smartphones, tablets, IoT | Mobile/IoT device makers and module houses | Disclosed in 1H2023 and FY2024 segment definitions | Market pricing | — |
| General electronic components | Other ICs and components; AR2025 records a HK$1.3 M inventory provision on long-aged "other electronic component products" | Electronics manufacturers and traders | From July 2019 | Market pricing | — |
| CPUs and semiconductors (historical) | Central processing units and semiconductors described in earlier segment definitions | Electronics manufacturers | 2019–2022 | Market pricing | — |
| Value-added services (historical, not separately charged) | Warehousing and quality-control services to meet customer-specific needs | Trade customers | Described in Interim Report 2022 | Bundled | — |
| Planned: customisation, assembly, packaging, testing, technical support | Proposed new manufacturing facilities in the PRC and other locations | Existing customers | Announced as a prospect in AR2025; no capex committed | — | — |
Health-care products and food segment
| Product line | Description | Target customer | Period | Pricing model | Named offerings |
|---|---|---|---|---|---|
| American ginseng (Panax quinquefolius) — cultivated and wild | The historical core: procurement in the US and Canada and wholesale in Hong Kong | Hong Kong wholesalers/retailers | 1989–2023 (disclosed through AR2021–AR2023) | Wholesale | — |
| Chinese herbal medicines | Traditional herbal products | Wholesalers/retailers | 2019–present | Wholesale | — |
| Ginseng wine / health beverages | Positioned as a premium dietary supplement for health-conscious consumers; marks the 2025 "re-entry" into health products | Wholesalers/retailers | Sourcing from FY2024; first sales FY2025 | Wholesale | — |
| Healthcare wine (historical) | Listed among major products in FY2018 | Wholesalers/retailers | 2,018 | Wholesale | — |
| Skin-care products | Commenced trading in 2025 | Wholesalers/retailers | 2019–2021; re-launched 2025 | Wholesale | — |
| Body-care products & supplements | Management negotiating authorised-distributor arrangements with manufacturers | Wholesalers/retailers | Pipeline (AR2025) | — | — |
Discontinued businesses
| Business | Description | Status |
|---|---|---|
| Money lending (Qianhai Health Finance Ltd) | Licensed money lender from Aug 2015; loan and interest receivables disclosed in AR2018–AR2019 | No longer reported as an activity |
| PRC "big health" projects | Hospitals, health check centres, senior housing, health resorts, Hangzhou platform (AR2017) | Not pursued in recent filings |
| Joint venture (equity-accounted) | Share of results of a joint venture referenced in 1H2021 and 1H2022 announcements | — |
Financial Narrative
All figures HK$ M unless stated. Primary sources: AR2021, AR2022 financial highlights; FY2023 RA; FY2024 RA; AR2025. FY2021–FY2022 EPS restated by analyst for the 10:1 consolidation (FY2022 reported −13.79 HK cents pre-consolidation).
Income statement: notes and sources
FY2021 and FY2022 EBITDA from TipRanks aggregation (HK$2.06 M and HK$−231.24 M); FY2023 EBITDA reconciles to TipRanks (−50.23). FY2024 EBITDA includes the HK$51.9 M disposal gain, HK$60.4 M onerous-contract provision and HK$4.2 M PPE impairment. FY2025 cost of sales derived (revenue − gross profit).
Growth
Revenue CAGR FY2021–FY2025: +24.3% (from HK$283.4 M to HK$677.1 M). CAGR FY2020–FY2025: −2.3% (from HK$760.7 M). The choice of base year transforms the conclusion — the business has no secular growth trend; it oscillates with the memory cycle.
Balance sheet: notes and sources
Goodwill/intangibles: none disclosed in the balance sheets reviewed (FY2023–FY2024 show PPE as the only non-current asset). FY2021–FY2022 NAV per share restated by analyst from reported HK$0.40 and HK$0.26. FY2025 net current assets per AR2025. Note: AR2025 MD&A states equity per share as "HK2.3 cents" — this appears to be a typographical error; the financial highlights show HK$2.31.
Interim balance sheet (30 Jun 2026, 1H2026 IR): total assets HK$441.4 M (+8.1% vs Dec 2025); inventories HK$231.4 M (roughly 4x Dec 2025); cash HK$17.9 M (−70.9%); contract liabilities (customer advances) HK$32.4 M; current ratio 8.9x; no bank borrowings.
Cash flow: notes and sources
Given no borrowings, no dividends, no buybacks and no material investments (AR2025), the FY2025 cash increase of HK$38.1 M is likely dominated by operating cash flow (inventory liquidation of ~HK$134 M offset by receivables build of ~HK$124 M). No shares were repurchased in FY2024 or FY2025 (AR2025; FY2024 RA).
Ratios — analyst-derived on year-end balances: notes and sources
Current ratios for FY2023–FY2025 are as reported (FY2024 RA; AR2025). Payables are negligible (accruals ~HK$2 M) so DPO ≈ 0; supplier prepayments are an additional working-capital drain not captured in the CCC.
Half-year P&L tracker: notes and sources
1H2024 net profit derived from 1H2025's reported −69.3% decline (HK$4.774 M). 1H2023 net result not captured. Sources: 1H2022 RA; 1H2024 RA; wire summaries of 1H2025 (20 Aug 2025) and 1H2026 (12 Aug 2026) results.
Commentary on trends, inflections and drivers
Revenue. The revenue line is a function of memory-chip prices multiplied by the volume of product management can source and is willing to carry. FY2022's HK$1.96 bn peak followed the 2022 supply master agreement and a deliberate scale-up in electronics; it collapsed by 51% in FY2023 and a further 46% in FY2024 as prices fell and the group reduced volumes amid intense competition (FY2024 RA). FY2025's 30% rebound was price-driven: AR2025 reports TLC wafer prices rising more than 65% month-on-month at points in 2025, partly offset by lower volumes because upstream shortages limited what the group could buy. The 1H2026 collapse (−65.7%) is the same shortage at a more acute stage — management attributed it to manufacturers reallocating capacity to AI memory (HBM, DDR5).
Gross margin. Margins are structurally thin (3–6%) for a broker without franchise rights. The negative FY2023 margin reflects selling inventory below carrying cost. The FY2024 recovery to 5.7% came from higher-margin product mix and a Q1 2024 price rebound; FY2025 compressed to 3.5% because competition intensified even as prices rose. The 1H2026 improvement to 6.6% came from selective pricing and mix, on far lower volume.
Below gross profit — the real swing factor. Every year's bottom line has been dominated by non-recurring items: FY2022 (−HK$323 M of inventory and onerous-contract provisions), FY2024 (+HK$51.9 M disposal gain, −HK$60.4 M onerous-contract provision, −HK$4.2 M PPE impairment), FY2025 (−HK$2.6 M ECL, −HK$1.3 M inventory provision). Recurring overhead is small (administrative expenses ~HK$15–17 M/year; 1H2026 HK$6.8 M, down 27.9%). This means the group needs roughly HK$15–17 M of annual gross profit to break even before one-offs.
Balance sheet. Equity has fallen from HK$670.5 M (FY2021) to ~HK$391 M, almost entirely through the FY2022 loss. Since then it has been stable. The group is unlevered and the balance sheet is essentially a working-capital fund: at 31 Dec 2025, ~HK$327 M of HK$408 M total assets was inventory, receivables and supplier prepayments. Composition shifts violently: inventory fell from HK$329.8 M (FY2023) to HK$54.9 M (FY2025), then rebuilt to HK$231.4 M by June 2026 while cash fell to HK$17.9 M — a renewed directional bet on memory prices.
Credit risk is rising. Trade receivables more than doubled to HK$222.7 M in FY2025, against revenue up only 30%; DSO lengthened to ~120 days and ECL provisions rose to HK$2.6 M. Given the top customer accounts for ~69% of sales, a single default could erase several years of profit. A HK$2.03 M ECL reversal in 1H2026 suggests some collection progress.
Returns. ROE has not exceeded 1.5% since FY2021 and averages deeply negative over five years; the business has destroyed roughly HK$280 M of book value since FY2021.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Segment Overview
| Segment | Contents | Products/services | Segment measure reported |
|---|---|---|---|
Electronic component products | Sale of information-technology component products | NAND flash wafers; embedded multi-chip package (eMCP) memory; other electronic components (historically also CPUs and semiconductors) | Segment result = gross profit; no segment assets/liabilities reported |
Health-care products and food | Sale of health-care products and food | Chinese herbal medicines (incl. American ginseng), health drinks/ginseng wine, skin-care and body-care products | Segment result = gross profit |
Revenue by Segment
| Segment (HKD Mn) | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Electronic component products revenue | 185.3 | 1,952.2 | 954.1 | 519.7 | — |
Health-care products and food revenue | 98.1 | 9.5 | 7.2 | 0 | — |
Total revenue | 283.4 | 1,961.7 | 961.3 | 519.7 | 677.1 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansResults by Segment
| Segment result (HKD Mn) | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Electronic component products gross profit | 14.3 | 76.2 | -35.8 | 29.7 | — |
Health-care products and food gross profit | 1.7 | 0.3 | 0.2 | 0 | — |
Total gross profit | 16.0 | 76.5 | -35.6 | 29.7 | 23.6 |
Segment margin (%)
| Segment margin (%) | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Electronic component products gross margin | 7.7 | 3.9 | -3.8 | 5.7 | — |
Health-care products and food gross margin | 1.8 | 2.8 | 2.4 | — | — |
Group gross margin | 5.7 | 3.9 | -3.7 | 5.7 | 3.5 |
Segment Margins & Growth (%) and Revenue by Segment (%)
| Metric (%) | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Electronic components revenue YoY growth | — | 953.7 | -51.1 | -45.5 | — |
Health-care revenue YoY growth | -77.9 | -90.3 | -24.5 | -100.0 | — |
Electronic components % of total revenue | 65.4 | 99.5 | 99.3 | 100.0 | 90 |
Health-care % of total revenue | 34.6 | 0.5 | 0.7 | 0.0 | 10 |
Revenue by Segment (1H2022–1H2026)
| Segment (HKD Mn) | 1H2022 | 1H2023 | 1H2024 | 1H2025 | 1H2026 |
|---|---|---|---|---|---|
Electronic components revenue | 1,201.3 | 337.2 | 307.0 | 338.7 | 114.5 |
Health-care revenue | 0 | 2.7 | 0 | 1.7 | 2.3 |
Electronic components gross profit | 28.2 | -6.4 | 42.9 | — | 7.3 |
Health-care gross profit | 0 | 0 | 0 | — | 0.5 |
Income Statement and Per-Share Data
| Metric (HKD Mn) | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Revenue | 283.4 | 1,961.7 | 961.3 | 519.7 | 677.1 |
Cost of sales | 267.4 | 1,885.2 | 996.9 | 490.0 | 653.5 |
Gross profit | 16.0 | 76.5 | -35.6 | 29.7 | 23.6 |
Other income | — | — | 0.1 | 0.2 | — |
Other gains/(losses), net | — | — | -0.5 | -12.8 | -1.5 |
ECL (provision)/reversal on receivables | — | — | 0.2 | -0.3 | -2.6 |
Administrative expenses | — | — | 16.6 | 15.3 | — |
Finance costs | — | — | 0.04 | 0.02 | — |
Operating income (EBIT, analyst-derived) | — | — | -52.7 | 1.3 | — |
Depreciation | 2.4 | 2.4 | 2.4 | 2.4 | — |
EBITDA (analyst-derived: EBIT + depreciation) | 2.1 | -231.2 | -50.2 | 3.7 | — |
Pre-tax income | -0.9 | -233.7 | -52.7 | 1.3 | 5.9 |
Income tax | 0 | 0 | 0 | 0 | 0 |
Net income attributable to owners | -0.9 | -233.7 | -52.7 | 1.3 | 5.9 |
Basic/diluted EPS (HK cents, post-consolidation basis) | -0.52 | -137.9 | -31.10 | 0.77 | 3.51 |
Dividends per share (HK cents) | 0 | 0 | 0 | 0 | 0 |
Margin Analysis (%)
| Metric (%) | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Gross margin | 5.7 | 3.9 | -3.7 | 5.7 | 3.5 |
Operating (EBIT) margin | — | — | -5.5 | 0.3 | — |
EBITDA margin | 0.7 | -11.8 | -5.2 | 0.7 | — |
Pre-tax margin | -0.3 | -11.9 | -5.5 | 0.3 | 0.9 |
Net margin | -0.3 | -11.9 | -5.5 | 0.3 | 0.9 |
Margin Analysis (%) — Revenue YoY growth
| Metric (%) | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Revenue YoY growth | -62.7 | 592.2 | -51.0 | -45.9 | 30.3 |
Balance Sheet and Per-Share Data
| Metric (HKD Mn) | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Total assets | 738.6 | 534.4 | 478.1 | 407.3 | 408.4 |
Property, plant & equipment | — | — | 26.5 | 21.2 | — |
Inventories | — | — | 329.8 | 188.8 | 54.9 |
Trade receivables | — | — | 0 | 98.7 | 222.7 |
Prepayments for inventory purchase | — | — | 102.0 | 70.6 | 49.0 |
Cash & cash equivalents | — | — | 19.5 | 23.3 | 61.4 |
Short-term bank borrowings | 7.2 | 0 | 0 | 0 | 0 |
Long-term debt | 0 | 0 | 0 | 0 | 0 |
Lease liabilities | — | — | 0.5 | 1.0 | — |
Provision for onerous contracts | — | — | 92.2 | 18.4 | — |
Total liabilities | 68.1 | 97.7 | 94.0 | 21.7 | 17.2 |
Total equity | 670.5 | 436.7 | 384.1 | 385.6 | 391.3 |
Goodwill & intangibles | 0 | 0 | 0 | 0 | 0 |
Net current assets (working capital) | 622.4 | 408.3 | 357.6 | 364.8 | 371.6 |
Net debt (cash) (analyst-derived, excl. leases) | — | — | -19.5 | -23.3 | -61.4 |
NAV per share (HK$, post-consolidation) | 3.96 | 2.58 | 2.27 | 2.28 | 2.31 |
Cash Flow
| Metric (HKD Mn) | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Dividends paid | 0 | 0 | 0 | 0 | 0 |
Share buybacks | 0 | 0 | 0 | 0 | 0 |
Net change in cash (analyst-derived from balance sheet) | — | — | — | 3.7 | 38.1 |
Returns & Leverage Ratios (%) and Financial Ratios (x)
| Ratio | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
ROE (%) | -0.1 | -53.5 | -13.7 | 0.3 | 1.5 |
ROA (%) | -0.1 | -43.7 | -11.0 | 0.3 | 1.5 |
ROIC (%, EBIT/(equity+debt−cash)) | — | — | -14.4 | 0.4 | — |
Current ratio (x) | — | — | 4.8 | 18.1 | 22.6 |
Gearing — total liabilities/total assets (%) | 9.2 | 18.3 | 19.7 | 5.3 | 4.2 |
Debt/equity (%) | 1.1 | 0 | 0 | 0 | 0 |
Net debt/EBITDA (x) | — | — | — | -6.2 | — |
Interest coverage (EBIT/finance cost, x) | — | — | — | 58 | — |
Asset turnover (revenue/total assets, x) | 0.38 | 3.67 | 2.01 | 1.28 | 1.66 |
Days inventory outstanding | — | — | 121 | 141 | 31 |
Days sales outstanding | — | — | 0 | 69 | 120 |
Cash conversion cycle (days, excl. prepayments) | — | — | 121 | 210 | 151 |
Income Statement and Margin Analysis (%)
| Metric (HKD Mn) | 1H2022 | 1H2023 | 1H2024 | 1H2025 | 1H2026 |
|---|---|---|---|---|---|
Revenue | 1,201.3 | 339.9 | 307.0 | 340.4 | 116.8 |
Gross profit | 28.2 | -6.4 | 42.9 | 14.2 | 7.7 |
Gross margin (%) | 2.3 | -1.9 | 14.0 | 4.2 | 6.6 |
Net profit attributable | 19.6 | — | 15.6 | 4.8 | 2.8 |
EPS (HK cents) | — | — | — | 2.82 | 1.68 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansRevenue by Region
| Region (HKD Mn) | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Hong Kong (point of delivery) | 283.4 | 1,961.7 | 961.3 | 519.7 | 677.1 |
Mainland China | 0 | 0 | 0 | 0 | 0 |
Rest of world | 0 | 0 | 0 | 0 | 0 |
Growth (%)
| Growth (%) | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Hong Kong revenue YoY growth | -62.7 | 592.2 | -51.0 | -45.9 | 30.3 |
Revenue by Region (FY2023–FY2024)
| Segment × geography (HKD Mn) | FY2023 | FY2024 |
|---|---|---|
Electronic components — Hong Kong | 954.1 | 519.7 |
Health-care — Hong Kong | 7.2 | 0 |
Share Price History
| Date | Price | Comment | Source |
|---|---|---|---|
~9 May 2025 | 0.205 | Market cap ~HK$34.7 M | moomoo |
Early 2026 (pre-spike) | 0.285 | — | etnet |
27 Apr 2026 | 0.84 intraday | More than doubled | etnet |
29 Apr 2026 | 1.22 intraday | More than doubled; 52-week high observed | etnet |
3 Jul 2026 | 0.66 | — | etnet |
~8 Jul 2026 | 0.72 | Market cap ~HK$122 M | Lixinger |
15 Jul 2026 | 0.81 | — | etnet |
29 Jul 2026 | 0.61 | Last verified quote; market cap ~HK$103 M | etnet |
Valuation Multiples
| Multiple | Qianhai Health | Basis |
|---|---|---|
Market capitalisation | HK$103.4 M | 169.445 M shares × HK$0.61 |
Enterprise value | ~HK$85.5 M | Market cap less HK$17.9 M cash (30 Jun 2026); no debt |
P/E (TTM) | ~25.8x | TTM profit ~HK$4.0 M (FY2025 HK$5.94 M − 1H2025 HK$4.77 M + 1H2026 HK$2.84 M) |
P/E (FY2025) | ~17.4x | — |
P/B | ~0.26x | Equity HK$391.3 M (Dec 2025) |
EV/Sales (TTM) | ~0.19x | TTM revenue ~HK$453 M |
EV/EBITDA | Not computable | — |
Lixinger reported (early Jul 2026, HK$0.72) | P/E 20.5x; P/B 0.31x | Lixinger |
Capital Markets
| Item | Status |
|---|---|
Dividend history | No dividends declared for FY2021–FY2025 or 1H2026 (ARs; 1H2026 IR) |
Dividend policy | Board-discretionary policy considering performance, reserves, working capital, liquidity and conditions; no payout target (AR2025) |
Distributable reserves | HK$258.4 M (31 Dec 2025) |
Share option mandate | 16,944,500 shares (10%) under 2024 scheme; none granted |
Credit ratings (Moody's/S&P/Fitch) | Not rated |
Debt maturity profile | Not applicable — no borrowings; only small lease liabilities |
Analyst consensus | No sell-side coverage identified |
Analyst Conclusions
Management guidance
No numerical guidance. Qualitatively, AR2025 expects the NAND wafer shortage to persist near term and positions the company to secure inventory, invest in downstream facilities and rebuild health-care. The 24 Jul 2026 profit warning (−35% to −45%) was the only quantified forward statement in 2026 and proved accurate (−36.7%).
Consensus expectations
None — no analyst coverage.
Bull case
-
Inventory leverage to a memory super-cycle. With HK$231 M of inventory at June 2026 (vs HK$55 M at Dec 2025) and WSTS forecasting memory revenue up roughly 250% in 2026, every 10% rise in realisable value on that inventory equals ~HK$23 M — roughly four years of recent profit.
-
Deep discount to tangible book. At ~0.26x P/B with no debt, no goodwill and HK$258 M of distributable reserves, the market prices in substantial further losses; even modest normalised ROE would justify re-rating.
-
Change-of-control optionality. The receivership over 52.67% could lead to a sale of the control block, which in Hong Kong generally triggers a mandatory general offer to minorities — a potential catalyst.
Bear case
-
Repeat of FY2022. The group re-loaded inventory into a price spike; a memory price correction would reproduce the FY2022 pattern (HK$323 M of provisions against equity then of HK$670 M).
-
Concentration and credit. One customer at ~69% of sales and receivables of HK$223 M (more than half of equity) leave the company exposed to a single default.
-
Structural disadvantage and governance overhang. Without franchise allocation, the group loses volume exactly when prices are best (FY2025, 1H2026); it has no CEO, its controlling stake is in receivership, and value creation since FY2021 has been negative.
Key catalysts and monitorables (next 12 months)
| Catalyst / monitorable | Timing | Why it matters |
|---|---|---|
| Receivers' actions on the 52.67% stake | Any time | Change of control / possible general offer |
| Memory (NAND) spot price trajectory | Continuous | Drives inventory gains/losses on HK$231 M stock |
| FY2026 annual results and any profit alert | Feb–Mar 2027 | Test of inventory value and receivables quality |
| Receivables collection / ECL movements | FY2026 results | Credit risk |
| Customer advances (HK$32.4 M contract liabilities) conversion to revenue | 2H2026 | Indicates 2H revenue recovery |
| Capex commitment to PRC facilities | Unspecified | Strategic credibility; cash use |
| CEO appointment | Unspecified | Governance |
| Litigation outcomes (CAD 2.8 M claim; Beijing dispute) | Unspecified | Unprovided contingent liability |
| Exchange queries on trading volatility | Unspecified | Regulatory risk |
Concluding analyst verdict
Qianhai Health Holdings should be analysed not as a health company but as a lightly capitalised, debt-free memory-chip trading book wrapped in a listed shell with an unstable ownership structure. The financial history is unambiguous: revenue has swung from HK$283 M to HK$1.96 bn and back to HK$677 M in four years, gross margins have ranged from −3.7% to 5.7%, and the only material profit since FY2019 came from a one-off disposal gain. Book value has shrunk by roughly 40% since FY2021, almost entirely from a single cycle turn in 2022. The core economic proposition — buying memory in bulk ahead of price moves and reselling to a handful of customers — has positive expected value only if management's timing is consistently right, and the 2022 episode shows the downside when it is not.
The current set-up is unusually binary. On one side, the group sits on inventory roughly four times its year-end 2025 level during what WSTS describes as an extraordinary memory upswing, trades at about a quarter of book, carries no debt and could become the subject of a control transaction because receivers now hold the 52.67% stake. On the other, it lacks franchise allocation, depends on one customer for most of its sales, has more than half its equity tied up in receivables, has gone seven years without a CEO, and has a board member linked to the creditor group holding the security over the control block.
For institutional investors the stock is effectively uninvestable on liquidity grounds alone (daily turnover can be in the tens of thousands of Hong Kong dollars). For special-situations investors, the thesis rests on two variables outside management's operating control: the memory price path and the outcome of the receivership. We would characterise the shares as a high-risk, event-driven option on asset value rather than a fundamental compounder, and we would require visibility on the receivers' intentions and on receivable collections before assigning weight to the book-value discount.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Board of Directors
| Name | Role | Age (AR2025) | Appointed | Prior roles / background | Education |
|---|---|---|---|---|---|
Mr. Huang Zhiqun (黃志群) | Chairman, non-executive director; authorised representative; ultimate controlling shareholder (52.67% via Explorer Rosy) | 51 | ED 12 Apr 2019; re-designated NED 17 Jul 2019 | 20+ years in electronic-components trading; ran own trading firm 1999–2003; co-founded a Hong Kong-based global component trading and distribution group in 2003 (CEO since), with presence in HK, PRC, Southeast Asia; co-founded a semiconductor manufacturing and trading group in 2005; standing director, Shenzhen Chao Shan Chamber of Commerce since Dec 2011 | — |
Mr. Chen Kaiben (陳凱犇) | Non-executive director | 40 | 3 Sep 2021 | ED of Solis Holdings (2227.HK) Oct 2020–Aug 2021; NED of Glory Sun Financial (1282.HK) and Glory Sun Land (299.HK) 2018–2019; Shenzhen Bao Da Financial Services; Dasheng Times Cultural Investment (600892.SH) | BBA (logistics & supply chain), Guangdong University of Foreign Studies, 2007 |
Mr. Chen Qi (陳琦) | Non-executive director | 35 | 3 Sep 2021 | Vice GM, operational management, Yunnan Energy Investment (HK) Co. Ltd since Jun 2020; earlier Yunnan Energy Finance Holdings and Yunnan Energy International (Singapore) | BA finance management, Yunnan University of Finance and Economics, 2015 |
Mr. Yuen Chee Lap Carl (源自立) | Executive director; member, remuneration & nomination committees | 52 | INED 29 Feb 2016; re-designated ED 23 Aug 2024 | 2004–May 2024 financial controller, CEO and COO of Courage Investment Group (1145.HK / SGX); US chief accountant roles 1998–2003 | BBA 1997, MBA 1998, University of Houston |
Mr. Tang Yu Yuan (湯裕源) | Executive director | 60 | 1 Oct 2024 | 28+ years in electronic-component and semiconductor distribution with Taiwanese technology companies | BEng Electronic Engineering, "National Southeast University" in Taiwan (as stated in AR2025) |
Mr. Li Wei (李偉) | INED; chair of remuneration and nomination committees; audit committee member | 71 | 17 May 2016 | 25+ years establishing businesses in Asia; INED of VSTECS Holdings (856.HK) since 2007 | Educated in China, Germany and Australia |
Mr. Leung Chun Tung (梁振東) | INED; audit, remuneration, nomination committees | 71 | 1 Mar 2022 | 39 years at Bank of China (Hong Kong), last as senior corporate loan manager | Executive MBA, Sun Yat-sen Business School / International East-West University |
Ms. Wu Hung Yu (胡紅玉) | INED; audit committee chair; nomination committee (from 25 Jun 2025) | 45 | 22 Nov 2024 | Ex-international accounting firms (audit, M&A, IPOs); INED of i-Control Holdings (1402.HK) and Well Link Securities (8350.HK) | BA Accountancy, Hong Kong Polytechnic University 2003; ACCA (2008), HKICPA (2009) |
“—” = not publicly disclosed.
Executive Leadership Team
| Name | Title | Age | Joined | Background |
|---|---|---|---|---|
Ms. Yip Tak Yung Teresa | Chief financial officer and company secretary | 44 | 2013 | Ex-Deloitte; INED of Guangdong Topstar Technology (300607.SZ); HKICPA member; BBA (Hons) accountancy, City University of Hong Kong |
Chief executive officer | Vacant since 18 Jul 2019 | — | — | Company states it is still identifying a suitable candidate (AR2025) |
Directors' Remuneration
| Item | FY2025 | Source |
|---|---|---|
Share-based compensation | Nil — no options granted under the 2024 scheme; 1.692 M legacy options (held by a customer's shareholder, not directors) lapsed on 2 Jul 2025 | AR2025 |
Total employee benefit expense (group) | FY2024 HK$6.57 M; FY2023 HK$6.45 M | FY2024 RA note 9 |
Directors' Remuneration (Status (AR2025))
| Attribute | Status (AR2025) |
|---|---|
Board size | 8 (3 NED, 2 ED, 3 INED) |
Independence | 3 of 8 (37.5%) — meets HKEX minimum of one-third |
Gender | 1 female director of 8 (12.5%); workforce 57% male / 43% female |
Chair/CEO separation | Chair is non-executive; CEO role vacant since 2019 — executive authority sits with two EDs and the CFO |
Audit committee | Wu Hung Yu (chair), Li Wei, Leung Chun Tung — all INEDs; 2 meetings in FY2025 |
Remuneration committee | Li Wei (chair), Yuen Chee Lap Carl, Leung Chun Tung; 1 meeting |
Nomination committee | Li Wei (chair), Yuen Chee Lap Carl, Leung Chun Tung, Wu Hung Yu; 2 meetings |
Board meetings / attendance | 6 meetings, 100% attendance by all directors (FY2025) |
Long-tenure INED | Li Wei has served >9 years (since May 2016) — under the revised HKEX CG Code (effective 1 Jul 2025), long-serving INEDs attract heightened scrutiny |
Director with link to pledgee group | Chen Qi is a vice GM at Yunnan Energy Investment (HK), which owns ~40% of the parent of the pledgee of the controlling stake — a material governance linkage (AR2025) |
D&O insurance | In place |
Board & Management Changes
| Date | Change | Context |
|---|---|---|
23 Aug 2024 | Yuen Chee Lap Carl re-designated INED → ED | Ex-Courage Investment CEO/COO; strengthens executive bench after his departure from Courage in May 2024 |
21 Sep 2024 | Chan Lap Kwong (陳立光) resigns as ED | Reason not captured |
1 Oct 2024 | Tang Yu Yuan appointed ED | Semiconductor distribution specialist |
22 Nov 2024 | Lin Jie (林捷) resigns as NED; Wu Hung Yu appointed INED and audit chair | Restores accounting expertise on the audit committee |
25 Jun 2025 | Wu Hung Yu joins nomination committee | Board diversity |
17 Jun 2026 | AGM re-elects retiring directors (Huang Zhiqun, Leung Chun Tung, Li Wei were scheduled to retire and stand for re-election) and re-appoints McMillan Woods | — |
Pre-2023 | Mr. | Interim Report 2022 |
Major Shareholders
| Holder | Shares | % | Nature | Source |
|---|---|---|---|---|
Explorer Rosy Limited (Huang Zhiqun 80% / Huang Jinglin 20%) | 89,248,577 | 52.67 | Beneficial owner; pledged to Yunnan International Supply Chain Ltd; receivers appointed | AR2025 |
Huang Zhiqun (direct) | 169,000 | 0.10 | Beneficial owner | AR2025 |
Yunnan Provincial Energy Investment Group / Yunnan Energy Investment (HK) / Yunnan International Holding Group / Yunnan International Supply Chain | 89,248,577 | 52.67 | Security interest (same shares) | AR2025 |
Alan C W Tang, Hou Chung Man; SHINEWING SAS (Nominee Services) No. 3 Ltd | 89,248,577 | 52.67 | Joint and several receivers (same shares) | AR2025 |
Public float (approx.) | ~80,027,423 | ~47.2 | Company confirms sufficient public float | AR2025 (derived) |
Competitive Landscape
Key Competitors
| Competitor | Segment overlap | Type | Latest revenue | Relative positioning |
|---|---|---|---|---|
Arrow Electronics (NYSE: ARW) | Electronic components | Global franchised distributor | ~US$27.9 bn FY2024 | ~400x larger; franchise lines, design-in services |
Avnet (NASDAQ: AVT) | Electronic components | Global franchised distributor | ~US$22.5 bn FY2025 (Jun YE) | Same |
WPG Holdings (2702.TW) | Electronic components | Asia's largest component distributor | — | Dominant Asia franchised share |
WT Microelectronics (3036.TW) | Electronic components incl. memory | Asian franchised distributor | — | Memory-heavy, large scale |
S.A.S. Dragon Holdings (1184.HK) | Memory and components distribution | HK-listed distributor | — | Direct HK-listed memory peer; far larger |
Willas-Array Electronics (0854.HK) | Components distribution | HK-listed distributor | — | Franchised lines in HK/PRC |
Shenzhen Huaqiang Industry (000062.SZ) | Components distribution & trading platforms | PRC distributor | — | Large PRC platform |
VSTECS Holdings (0856.HK) | IT products distribution (adjacent) | HK-listed IT distributor | — | Adjacent; note Qianhai INED Li Wei is also INED there |
Unlisted Hong Kong/Shenzhen spot-market memory traders | Electronic components | Independent brokers | — | Most direct competitors; intense price competition cited in FY2024 RA and AR2025 |
Hong Kong ginseng and herbal wholesalers (e.g., Sheung Wan Ko Shing Street traders; Hin Sang Group 6893.HK in health products) | Health-care | Wholesalers / consumer health | — | Qianhai now sub-scale in this segment |
“—” = not publicly disclosed.
Peer Comparison FY2025
| Metric | Qianhai Health (FY2025) | Arrow (FY2024) | Avnet (FY2025) |
|---|---|---|---|
Revenue | HK$677 M (~US$87 M) | ~US$27.9 bn | ~US$22.5 bn |
Revenue growth | +30.3% | — | — |
Gross margin | 3.5% | — | — |
Net margin | 0.9% | — | — |
R&D intensity | 0% | Negligible (distribution model) | Negligible |
Employees | 19 | — | — |



